Skip to main content

5 Trends in Biotech & Pharma

  1. COVID continues to drive collaboration – The need for vaccines and therapeutics to treat COVID-19, its variants, and other diseases continues to drive collaboration between companies with innovative technologies being redeployed and combined to develop new treatments.

  2. It’s not only about oncology – While the focus on oncology remains strong, investment in other indications is increasing to drive valuations and deal-making for both M&A and partnering deals.

  3. Convergence will increase – The development and adoption of AI and other “tech” in the development of drugs and formulation of drug products, analysis of large data pools, clinical trials and other critical development pathways will continue to shake up traditional methods and pathways.

  4. Royalty monetization will continue to grow – Expect to see more players as the barriers to analyzing and executing royalty monetization deals fall and companies look to these deals as options for nondilutive financing.

  5. Global deal-making - the world has adapted – In a Covid world, global deal making has increased both for M&A and partnering deals. Parties have adapted to a remote model and have not let Covid impair executing and closing deals. 2022 will continue these trends and will likely see the adoption of hybrid remote/in person practices even if in person travel and meeting opportunities increase.

About the Authors

Fiona Adams is the managing shareholder of Greenberg Traurig’s London office and the co-chair of the Global Corporate Practice. She primarily represents corporate clients, focusing her practice on mergers and acquisitions, and other transactional matters. 

David Dykeman, who serves as co-managing shareholder of Greenberg Traurig's Boston office and co-chairs the firm's global Life Sciences & Medical Technology Group, is a registered patent attorney with nearly 25 years of experience in patent and intellectual property law.

Wayne H. Elowe is co-chair of Greenberg Traurig’s global Life Sciences and Medical Technology Group and co-chair of the Corporate Practice in Atlanta. He concentrates his practice on corporate counseling, international business and complex commercial transactions, with an emphasis on mergers and acquisitions, joint ventures, strategic investments and alliances, licensing, and technology transactions.